

Device Therapy for Structural Heart Disease

This issue examines device therapy for structural heart disease. This area is of rapidly growing interest to all of us, and at the same time, it is an area that is not as well characterized in the literature as PCI and coronary disease. The contributors to this issue all bring experience and expertise to their articles, and I hope this issue will shed a great deal of light on the subject.

Andrew D. Michaels, MD, MAS, FACC, FAHA, opens our feature by walking us through the technical aspects of a successful patent foramen ovale closure procedure. Further, we have a helpful overview of the imaging modalities that best accompany PFO and atrial septal defect closure by John F. Rhodes, Jr, MD.

Mark D. Osten, MD, and Eric M. Horlick, MDCM, follow with a thorough discussion of the percutaneous closure of pulmonary arteriovenous malformations and coronary fistulas.

Next, Larry A. Latson, MD, and Athar M. Qureshi, MD, explain the many technical considerations that accompany catheter closure for atrial septal defect and may help minimize potential late complications.

Percutaneous management of paravalvular regurgitation has become a very favorable treatment option for closing defects resulting from prior valve placement. Jeffrey D. Booker, MD, and Charanjit S. Rihal, MD, discuss the technical aspects of treating this complex and challenging presentation.

Nikolaos Kakouros, BSc, MBBS, MRCP, and Stephen J.D. Brecker, MD, FRCP, FESC, FACC, explain the expanding application of transcatheter device closure for ventricular septal defect after an acute myocardial infarction.

To close our feature, Daniel R. Turner, MD,

FAAP, FACC, and Thomas J. Forbes, MD, FACC, FSCAI, discuss the progress that has been made in recent years in the transcatheter treatment of coarctation of the aorta.

In our Today's Practice column, Terrell J. Isselhard, JD, explains what steps and precautions to take when separating medical practices and ending a business relationship.

In our featured interview, we talk to Larry S. Dean, MD, about pertinent recent trial results, the upcoming SCAI and STEMI Summit meetings, and his future role as the President of the SCAI.

Our goal remains to synthesize the vast body of interventional cardiology literature into a manageable volume of reading. Please let us know if there are any special interests you would like to hear about in future issues. ■



A stylized, handwritten signature in black ink, appearing to read 'Ted Feldman'.

Ted E. Feldman, MD, FSCAI
Chief Medical Editor
citeditorial@bmctoday.com